Data and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals, Inc. (SNSS)' VALOR Trial With No Change to Study Conduct  
6/13/2013 8:53:50 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SOUTH SAN FRANCISCO, Calif., June 13, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the independent Data and Safety Monitoring Board (DSMB) for the VALOR trial has completed its latest periodic safety review and recommended that the trial continue as planned without changes to study conduct. The VALOR trial is a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin, Sunesis' lead product candidate, in patients with first relapsed or refractory acute myeloid leukemia (AML).

Help employers find you! Check out all the jobs and post your resume.